Aktienanalyse zu aTyr Pharma Inc (ATYR)ATYRaTyr Pharma Inc

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Currently, aTyr Pharma Inc is not a good buy. The stock is trading at $0.1651, which is significantly lower than its analyst price target of $3.50, indicating potential upside. However, the stock has seen a year-to-date change of -78.25% and a 1-year change of -83.04%, reflecting a severe downtrend. Additionally, the RSI is at 5.767, indicating that the stock is extremely oversold, but this could also suggest a lack of buying interest. The main risk is the company's ongoing financial losses, with a net income of -$10.31 million reported in Q2 2026, which raises concerns about its sustainability and ability to recover.